GGrantIndex
← Leaderboards

Ivan M Robbins

Vanderbilt University

$2,964,589
Attributed
$2,964,589
Total exposure
7
Grants
2
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).

Funding over time

peak $532.7K · FY200516
$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16

Funding mix

By agency

NIH$2,964,589 · 7

By mechanism

P01$2,285,872 · 1
K23$624,240 · 1
M01$44,477 · 4
R13$10,000 · 1

Top collaborators

No co-investigators on record.

Most similar at Vanderbilt University

Same institution · by research overlap

Others in their field

Top investigators on “Clinical Research

Research focus

Clinical ResearchHuman SubjectHuman Therapy EvaluationPulmonary HypertensionCardiovascular Disorder ChemotherapyProstacyclinsPharmacokineticsThromboxanesProstaglandinsPulmonary CirculationClinical TrialsDrug Administration RoutesRenin Angiotensin SystemCongenital Heart DisorderHemodynamicsExerciseEnzyme InhibitorsFundingLeukocyte Activation /TransformationDisease /Disorder EtiologyCooperative StudyCollaborationsAngiographyAce Inhibitors

Grant awards (25)

Clinical and Statistical Support Core/Loyd$423,064
P01 · FY2016 · HL · contact PI
Clinical and Statistical Support Core/Loyd$427,863
P01 · FY2015 · HL · contact PI
Clinical and Statistical Support Core/Loyd$104,864
P01 · FY2015 · HL · contact PI
Clinical and Statistical Support Core/Loyd$423,982
P01 · FY2014 · HL · contact PI
Clinical and Statistical Support Core/Loyd$432,045
P01 · FY2013 · HL · contact PI
Clinical and Statistical Support Core/Loyd$474,054
P01 · FY2012 · HL · contact PI
IXth International Pulmonary Hypertension Conference: Scientific Sessions$10,000
R13 · FY2010 · HL · contact PI
A PILOT STUDY COMPARING ANTI-PLATELET THERAPIES AND PLACEBO IN PULMONARY ARTE$460
M01 · FY2005 · RR
Mentored Patient-Oriented Research Career Development Aw$124,848
K23 · FY2004 · RR
A pilot study comparing anti-platelet therapies and placebo in pulmonary arte...$22,559
M01 · FY2004 · RR
Evaluation of Circulating Lipid and Protein Mediators in Patients$21,458
M01 · FY2004 · RR
Mentored Patient-Oriented Research Career Development Aw$124,848
K23 · FY2003 · RR
Mentored Patient-Oriented Research Career Development Aw$124,848
K23 · FY2002 · RR
CYCLOOXYGENASE 2 INHIB ON EICOSANOID IN PULMONARY HYPERT$0
M01 · FY2002 · RR
CHRONIC SUBCUTANEOUS UT 15/PATIENTS W/ PULMONARY HYPERTE$0
M01 · FY2002 · RR
Mentored Patient-Oriented Research Career Development Aw$124,848
K23 · FY2001 · RR
CYCLOOXYGENASE 2 INHIB ON EICOSANOID IN PULMONARY HYPERT$0
M01 · FY2001 · RR
CYCLOOXYGENASE 2 INHIB ON EICOSANOID IN PULMONARY HYPERT$0
M01 · FY2001 · RR
CYCLOOXYGENASE 2 INHIB ON EICOSANOID IN PULMONARY HYPERT$0
M01 · FY2001 · RR
CHRONIC SUBCUTANEOUS UT 15/PATIENTS W/ PULMONARY HYPERTE$0
M01 · FY2001 · RR
CHRONIC SUBCUTANEOUS UT 15/PATIENTS W/ PULMONARY HYPERTE$0
M01 · FY2001 · RR
CHRONIC SUBCUTANEOUS UT 15/PATIENTS W/ PULMONARY HYPERTE$0
M01 · FY2001 · RR
Mentored Patient-Oriented Research Career Development Aw$124,848
K23 · FY2000 · RR
CYCLOOXYGENASE 2 INHIB ON EICOSANOID IN PULMONARY HYPERT$0
M01 · FY2000 · RR
CHRONIC SUBCUTANEOUS UT 15/PATIENTS W/ PULMONARY HYPERTE$0
M01 · FY2000 · RR